News Details

PALM SPRINGS, Calif. – PerkinElmer Life and Analytical Sciences, a global leader in life science research, drug discovery and cellular science, today announced the launch of 20 new high-throughput microplates, which have been designed to augment the company's instrumentation and assay platforms. An exclusive feature is an innovative plate height designed for 1536-well microplates. The unique design has the same dimensions as 96-and 384-well plates, provides a single automation protocol, and can significantly reduce error. Widely used in life science research and drug discovery labs, the microplate technologies were exhibited at LabAutomation 2008, Jan. 27-30, Palm Springs, Calif., booth #427. “The microplate advancements demonstrate our commitment to optimize high-throughput screening and to support researchers, who must continually improve consistency in results, operational efficiency and error reduction,” said Dr. Richard Eglen, President, Molecular Medicine, PerkinElmer Life and Analytical Sciences.

With the new 1536-well microplate models, OptiPlate^™, CulturPlate^™, SpectraPlate^™ and AlphaPlate^™, there is no recalculation and height adjustment required when 96-and 384-well plates are changed to 1536-well plates. Many other 1536 well plates have heights of 8 or 10 mm, and involve two automation protocols. The new plates also have a wider gripping area, which enables more optimal robotic operations, and they meet standards established by the Society of Biomolecular Sciences (SBS) and the American National Standards Institute (ANSI).

The new light-gray AlphaPlate, which was designed specifically for AlphaScreen^® and AlphaLISA^™ biomarker detection assays, has been shown to significantly reduce crosstalk when compared to standard white 1536-well microplates. This provides for enhanced precision and greater sensitivity and signal amplification.

For more information about the new microplate technologies, visit www.perkinelmer.com/microplates.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer Inc.'s Life and Analytical Sciences business unit provides fully integrated, innovative solutions, leveraging deep scientific expertise and dedication to fulfilling customer needs to help scientists advance the pace and precision of their research and testing. It is a leading provider of diagnostic and detection instruments, reagents, software and services for advanced cellular science research and drug discovery, genetic screening, medical imaging, environmental, quality assurance and the health sciences industries.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE. www.perkinelmer.com or 1-877-PKI-NYSE.

For further information regarding PerkinElmer, please contact:

Media Contact:

Dara Cothran
Euro RSCG Worldwide PR
(212) 367-6814
dara.cothran@eurorscg.com